Literature DB >> 33914020

Changes in the Optic Nerve Head and Choroid Over 1 Year of Spaceflight.

Brandon R Macias1, Connor R Ferguson2, Nimesh Patel3, C Gibson4,5, Brian C Samuels6, Steven S Laurie5, Stuart M C Lee5, Robert Ploutz-Snyder7, Larry Kramer8, Thomas H Mader9, Tyson Brunstetter1, Irina V Alferova10, Alan R Hargens11, Douglas J Ebert5, Scott A Dulchavsky12, Michael B Stenger1.   

Abstract

IMPORTANCE: While 6-month data are available regarding spaceflight-associated neuro-ocular syndrome, manned missions for 1 year and beyond are planned, warranting evaluation for spaceflight-associated neuro-ocular syndrome beyond 6 months.
OBJECTIVE: To determine if the manifestation of spaceflight-associated neuro-ocular syndrome worsens during International Space Station missions exceeding the present 4- to 6-month duration. DESIGN, SETTING, AND PARTICIPANTS: The One-Year Mission Study used quantitative imaging modalities to investigate changes in ocular structure in 2 crew members who completed a 1-year-long spaceflight mission. This study investigated the ocular structure of crew members before, during, and after their mission on the International Space Station. Two crew members participated in this study from March 2015 to September 2016. Analysis began in March 2015 and ended in May 2020. EXPOSURES: Crew members were tested before, during, and up to 1 year after spaceflight. MAIN OUTCOMES AND MEASURES: This study compares ocular changes (peripapillary retinal edema, axial length, anterior chamber depth, and refraction) in two 1-year spaceflight mission crew members with cohort crew members from a 6-month mission (n = 11). Minimum rim width (the shortest distance between Bruch membrane opening and the internal limiting membrane) and peripapillary total retinal thickness were measured using optical coherence tomography.
RESULTS: Both crew members were men. Minimum rim width and total retinal thickness increased in both participants throughout the duration of spaceflight exposure to the maximal observed change from preflight (minimum rim width: participant 1, 561 [+149 from preflight] μm at flight day 270; participant 2, 539 [+56 from preflight] μm at flight day 270; total retinal thickness: participant 1, 547 [+135 from preflight] μm at flight day 90; participant 2, 528 [+45 from preflight] μm at flight day 210). Changes in peripapillary choroid engorgement, axial length, and anterior chamber depth appeared similar between the 1-year mission participants and a 6-month mission cohort. CONCLUSIONS AND RELEVANCE: This report documents the late development of mild optic disc edema in 1 crew member and the progressive development of choroidal folds and optic disc edema in another crew member over the duration of 1 year in low Earth orbit aboard the International Space Station. Previous reports characterized the ocular risk associated with 4 to 6 months of spaceflight. As future spaceflight missions are planned to increase in duration and extend beyond low Earth orbit, further observation of astronaut ocular health on spaceflight missions longer than 6 months in duration may be warranted.

Entities:  

Mesh:

Year:  2021        PMID: 33914020      PMCID: PMC8085766          DOI: 10.1001/jamaophthalmol.2021.0931

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  2 in total

Review 1.  Composites Additive Manufacturing for Space Applications: A Review.

Authors:  Sung Wook Paek; Sivagaminathan Balasubramanian; David Stupples
Journal:  Materials (Basel)       Date:  2022-07-05       Impact factor: 3.748

2.  Effects of Venoconstrictive Thigh Cuffs on Dry Immersion-Induced Ophthalmological Changes.

Authors:  Marc Kermorgant; Ayria Sadegh; Thomas Geeraerts; Fanny Varenne; Jérémy Liberto; François-Philippe Roubelat; Noémie Bataille; Marie-Pierre Bareille; Arnaud Beck; Brigitte Godard; Adrianos Golemis; Nathalie Nasr; Dina N Arvanitis; Ophélie Hélissen; Jean-Michel Senard; Anne Pavy-Le Traon; Vincent Soler
Journal:  Front Physiol       Date:  2021-07-14       Impact factor: 4.755

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.